Home Aldehydes 1-(4-Chlorobenzyl)-1h-indole-3-carbaldehyde

1-(4-Chlorobenzyl)-1h-indole-3-carbaldehyde

CAS No.:
75629-57-1
Catalog Number:
AG008PR6
Molecular Formula:
C16H12ClNO
Molecular Weight:
269.7256
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
95%
In Stock USA
United States
$129
- +
5g
95%
In Stock USA
United States
$316
- +
Product Description
Catalog Number:
AG008PR6
Chemical Name:
1-(4-Chlorobenzyl)-1h-indole-3-carbaldehyde
CAS Number:
75629-57-1
Molecular Formula:
C16H12ClNO
Molecular Weight:
269.7256
MDL Number:
MFCD01051808
IUPAC Name:
1-[(4-chlorophenyl)methyl]indole-3-carbaldehyde
InChI:
InChI=1S/C16H12ClNO/c17-14-7-5-12(6-8-14)9-18-10-13(11-19)15-3-1-2-4-16(15)18/h1-8,10-11H,9H2
InChI Key:
ZDRQMXCSSAPUMM-UHFFFAOYSA-N
SMILES:
O=Cc1cn(c2c1cccc2)Cc1ccc(cc1)Cl
Properties
Complexity:
314  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
269.061g/mol
Formal Charge:
0
Heavy Atom Count:
19  
Hydrogen Bond Acceptor Count:
1  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
269.728g/mol
Monoisotopic Mass:
269.061g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
22A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7  
Literature
Title Journal
Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. Journal of medicinal chemistry 20110428
(2Z,3E)-2-{[1-(4-Chloro-benz-yl)-1H-indol-3-yl]methyl-idene}quinuclidin-3-one oxime. Acta crystallographica. Section E, Structure reports online 20110301
Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PloS one 20110101
Oxidative stress in NSC-741909-induced apoptosis of cancer cells. Journal of translational medicine 20100101
Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Molecular cancer therapeutics 20090201
Properties